

Clinical trials of ximelagatran (without LMWH)

TrialResults-center www.trialresultscenter.org

1 venous thrombosis

| Trial | Treatments | Patients | Trials design and methods |
|--|---|-------------------------|---------------------------|
| ximelagatran (without LMWH) vs LMWH/VKA | | | |
| THRIVE I , 2003 n=NA follow-up: | oral ximelagatran (24, 36, 48 or 60 mg twice daily) for 2 weeks versus dalteparin and warfarin for 2 weeks | Patients with acute DVT | |

More details and results :

- antithrombotics for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q101>
- direct oral anticoagulant (DAO) for venous thrombosis in all types of patients at <http://www.trialresultscenter.org/go-Q505>

References

THRIVE I, 2003:

Eriksson H, Whlander K, Gustafsson D, Welin LT, Frison L, Schulman S A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003 Jan;1:41-7 [[12871538](#)]

Entry terms: ximelagatran, ximelagatran, xi-melagatran, Exanta, H 376 95, H 376-95,